Show simple item record

dc.contributor.authorThakkar, Parth
dc.date.accessioned2019-02-13T20:07:19Z
dc.date.available2019-02-13T20:07:19Z
dc.date.issued2019-02-13
dc.identifier.urihttp://hdl.handle.net/10675.2/622125
dc.descriptionPresentation given at the 20th Annual Phi Kappa Phi Student Research and Fine Arts Conferenceen
dc.description.abstractMore than 90% of head and neck cancer is head and neck squamous cell carcinoma1 (HNSCC). Currently, the treatment involves modern surgery, conventional chemotherapy, and radiation. However, targeting, the epidermal growth factor receptor (EGFR) has been shown to prove advantageous for patient survival. EGFR activation leads to cell cycle progression. Blocking the EGFR by an antibody results in the inhibition of the receptor, therefore inhibition of cell proliferation. This makes EGFR a prime target for anticancer therapy, specifically with tyrosine kinase inhibitors being looked at as a possible form of inhibition. The goal of this project was to hopefully use small molecule inhibitor EXO2 and an EGFR specific tyrosine kinase inhibitor, Erlotinib, in a synergistic manner to fight against HNSCC. This study was done using cell cultures, MTT assay�s and western blot techniques, with cell cultures being done using the H6 cell line. The results from this study were found to be a preliminary success and will pave the way for future experiments in this area.
dc.subjectHead Neck Canceren
dc.titleSYNERGISTIC EFFECTS OF THE COMBINATION OF ERLOTINIB & EXO2 ON HEAD AND NECK CANCERen
dc.typePoster Presentationen
dc.contributor.departmentDepartment of Biological Sciencesen
dc.contributor.departmentDepartment of Oral Biologyen
cr.funding.sourceAugusta University CURS Summer Scholars Programen
dc.contributor.sponsorTeng, Yongen
dc.contributor.affiliationAugusta Universityen
html.description.abstractMore than 90% of head and neck cancer is head and neck squamous cell carcinoma1 (HNSCC). Currently, the treatment involves modern surgery, conventional chemotherapy, and radiation. However, targeting, the epidermal growth factor receptor (EGFR) has been shown to prove advantageous for patient survival. EGFR activation leads to cell cycle progression. Blocking the EGFR by an antibody results in the inhibition of the receptor, therefore inhibition of cell proliferation. This makes EGFR a prime target for anticancer therapy, specifically with tyrosine kinase inhibitors being looked at as a possible form of inhibition. The goal of this project was to hopefully use small molecule inhibitor EXO2 and an EGFR specific tyrosine kinase inhibitor, Erlotinib, in a synergistic manner to fight against HNSCC. This study was done using cell cultures, MTT assay�s and western blot techniques, with cell cultures being done using the H6 cell line. The results from this study were found to be a preliminary success and will pave the way for future experiments in this area.


This item appears in the following Collection(s)

Show simple item record